By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Notification Show More
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Investing > Viking Therapeutics takes advantage of soaring stock price to issue fresh shares at a discount
Investing

Viking Therapeutics takes advantage of soaring stock price to issue fresh shares at a discount

News Room
Last updated: 2024/02/29 at 5:41 PM
By News Room
Share
3 Min Read
SHARE

Viking Therapeutics Inc., the clinical-stage biotech that wowed investors this week with promising data from a mid-stage trial of its weight-loss drug, is bolstering its balance sheet by issuing new shares.

The company, whose stock
VKTX,
-18.47%
has gained an impressive 129% in the week so far, priced a $550 million offering of 6.47 million shares at $85 a share late Wednesday, a discount over its closing price of $94.50.

Proceeds will be used for continued development of the weight-loss treatment VK2735 and NASH drug VK0214 and for R&D, working capital and general corporate purposes.

The stock was down 9% early Thursday in the pattern typical after a secondary offering which is dilutive to the existing shares.

Viking published the data from its Phase 2 trial dubbed Venture on Tuesday, sending its stock up 121% to a record that it broke on Wednesday. The stock is viewed as a cheaper entry for investors who want to play the mania around the new class of drugs, given that the two leaders in the space, Eli Lilly & Co.
LLY,
-0.52%
and Denmark’s Novo Nordisk
NVO,
-1.46%

NOVO.B,
-1.73%
have become relatively expensive.

VK2735 is Viking’s GLP-1 receptor agonist that it’s developing in both injectable and oral form as a treatment for obesity and diabetes.  use the same mechanism as Novo Nordisk’s Wegovy and Ozempic and Lilly’s Mounjaro, mimicking the effects of GLP-1, a gut hormone that can help control blood-sugar levels and reduce appetite. GLP stands for glucagon-like peptide.

Analysts praised the data and said the company has become an attractive target for Big Pharma.

“The GLP-1/GIP space is ultimately a large/mega cap pharma space, in our view,’ said Maxim analysts Naz Rahman and Jason McCarthy.

“Viking has to partner for commercialization or likely late stage development. Considering the competitive nature of the product and the blockbuster growing market, we believe this further increases Viking’s attractiveness as a potential acquisition target with Viking’s NASH program being upside.”

All 10 analysts polled by FactSet have a buy or equivalent rating on the stock, even though Viking does not yet have a fully approved product on the market.

Jefferies analysts introduced a note of caution on Wednesday with a note to clients that pointed out the Viking’s drug is unlikely to get to market until 2029+. But analysts led by Akash Tewaria acknowledged the trial data were impressive.

Check out On Watch by MarketWatch, a weekly podcast about the financial news we’re all watching — and how that’s affecting the economy and your wallet. MarketWatch’s Jeremy Owens trains his eye on what’s driving markets and offers insights that will help you make more informed money decisions. Subscribe on Spotify and Apple.  

Read the full article here

News Room February 29, 2024 February 29, 2024
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
The British state’s battle to contain the fallout from catastrophic Afghan data leak

Rarely has an email created such danger — or carried so high…

UK set up secret Afghan immigration scheme after data leak and gagged media

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

US bank earnings live: BlackRock hits record $12.5tn in assets as results season gets under way

BlackRock’s assets under management climbed to a record $12.5tn in the second…

Donald Trump asked Volodymyr Zelenskyy if Ukraine could hit Moscow, say people briefed on call

Donald Trump has privately encouraged Ukraine to step up deep strikes on…

The small mining company that won a big investment from the Pentagon

James Litinsky made a $100mn bet in 2015 on the distressed debt…

- Advertisement -
Ad imageAd image

You Might Also Like

Investing

Nursing Home Stocks Could Suffer from this Medicaid Spending Remedy

By News Room
Investing

Bitcoin Drops Below $90,000 Again. What Could Move It Next.

By News Room
Investing

These Stocks Are Moving the Most Today: Marvell, Nvidia, Broadcom, GM, Tesla, MongoDB, Burlington, and More

By News Room
Investing

Nvidia Stock Falls as Marvell Earnings Compound AI Gloom. The Rising Risks for Chips.

By News Room
Investing

This analyst says Tesla deliveries will be 16% below expectations. Musk is part of the problem.

By News Room
Investing

BP CEO was awarded no bonus pay from oil giant’s financial performance

By News Room
Investing

Shares of Starlink’s European competitor have tripled. CEO says it can do the job in Ukraine.

By News Room
Investing

GE Vernova Stock Rises as Analyst Flips to Upgrade After Rating Cut

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?